EarlyLifeStressInducedMechanisms of CardiovascularDiseaseRisk and Resilience
Project Number1P01HL158500-01A1
Former Number1P01HL158500-01
Contact PI/Project LeaderPOLLOCK, JENNIFER S
Awardee OrganizationUNIVERSITY OF ALABAMA AT BIRMINGHAM
Description
Abstract Text
OVERALL SUMMARY
Earlylifestress (ELS) is defined as stressful and traumatic events, such as household dysfunction, neglect,
sexual or physical abuse, economic hardship, and exposure to violence, experienced up to 18 years. ELS was
identified as a cardiovasculardisease (CVD) risk factor over 20 years ago, but mechanistic insights into its effects
remain very limited. Exposure to ELS is pervasive in the US with ~50% of children and adolescents having one
or more major ELS experiences. ELS exposure increases the risk traditional CVD risk factors - by the 3rd-4th
decade of life. A recent analysis of healthcare burden in Europe and North America attributed $748 billion in
annual costs to the effects of ELS, with 75% of those costs in people with multiple ELS exposures. The
significance of our work aligns with the NHLBI mission to promote the prevention and treatment of cardiovasculardiseases enhancing the health of all individuals to live longer and fulfilling lives. Among individuals with a history
of ELS exposure, vascular dysfunction (elevated peripheral vascular resistance, increased vascular stiffness)
and elevated diastolic blood pressure are already evident in early adulthood. The overall goal of our program
project grant (PPG) is to define mechanisms by which ELS leads to CVD risk and inform strategies for prevention
and effective treatment of CVD consequences in individuals exposed to ELS. This PPG will address two critical
barriers to fulfill our goal: 1) Need for ELS-specific in-depth mechanistic and translational studies; and, 2) Identify
modifiable protective factors that can reduce ELS-induced CVD risk. The overarching hypothesis of our PPG is
that ELS induces immune cell activation leading to vascular dysfunction with increased hypertension risk and
CVD risk that are exacerbated by later lifestressors or moderated by resilience/protective factors. This PPG with
both basic science and clinical projects utilizes a synergistic and integrative approach translating concepts from
clinically relevant rodent models to humans. Our group is extremely synergistic, with each leader bringing unique
expertise from different scientific backgrounds focused on our overall goal to understand mechanisms of ELS
induced indicators of CVD risk and resilience. Over the past several years, our team built strong collaborations
translating discoveries between basic and clinical labs with several pilot grants, co-mentoring trainees, and
multiple jointly authored abstracts, manuscripts, and publications. The four projects and three cores are
integrated in their goals and impact such that much more will be achieved together than separately. This PPG
utilizes a range of approaches to investigate in-depth molecular mechanisms of ELS-induced hypertension and
vascular diseaserisk as well as to delineate protective factors mediating resiliency to this risk. The results will
have important translational potential pointing to new intervention or prevention strategies for the health
consequences of CVD and reducing the healthcare burden of CVD.
Public Health Relevance Statement
OVERALL PROJECT NARRATIVE
The overarching hypothesis of our PPG states that earlylifestress (ELS), such as household dysfunction,
neglect, sexual or physical abuse, economic hardship, and exposure to violence induces immune cell activation
leading to vascular dysfunction with increased hypertension risk and CVD risk that are exacerbated by later lifestressors or moderated by resilience/protective factors. This PPG with both basic science and clinical projects
utilizes a synergistic and integrative approach translating concepts from animal models to humans with our major
goal being to inform prevention and intervention strategies to mitigate future CVD risk in individuals exposed to
ELS. Our PPG will address two critical barriers to fulfill our goal: 1) need for ELS-specific in-depth mechanistic
and translational studies; and, 2) identify modifiable protective factors that can mitigate ELS-induced CVD risk.
No Sub Projects information available for 1P01HL158500-01A1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1P01HL158500-01A1
Patents
No Patents information available for 1P01HL158500-01A1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1P01HL158500-01A1
Clinical Studies
No Clinical Studies information available for 1P01HL158500-01A1
News and More
Related News Releases
No news release information available for 1P01HL158500-01A1
History
No Historical information available for 1P01HL158500-01A1
Similar Projects
No Similar Projects information available for 1P01HL158500-01A1